Anti-CD3 Scfv-B7.1 Fusion Protein Expressed on the Surface of HeLa Cells Provokes Potent T-lymphocyte Activation and Cytotoxicitythis Paper is One of a Selection of Papers in This Special Issue, Entitled International Symposium on Recent Advances in Molecular, Clinical, and Social Medicine, and Has Undergone the Journal's Usual Peer-Review Process.

Zhang-Min Yang,En-Min Li,Bao-Chang Lai,Yi-Li Wang,Lu-Sheng Si

DOI: https://doi.org/10.1139/o07-013

2007-01-01

Biochemistry and Cell Biology

Abstract:The targeting of tumor cells by cytotoxic T lymphocytes is a promising strategy for biotherapy, but T cells require 2 signals via the T-cell receptor – CD3 complex and CD28 molecules for activation. To bridge the gap between cytotoxic T lymphocytes and tumor cells, our objective in this study was to describe the construction and the cell surface-anchored expression of a fusion protein, anti-CD3 scFv-B7.1, derived from inserting a fusion gene encoding anti-CD3 scFv and the extra-cellular domain of B7.1 fused by the splicing by overlap extension method into a mammalian expression vector, pDisplay. Transfection of the recombinant vector by electroporation into HeLa cells resulted in the production of protein migrating at approximately 57 kDa under reducing conditions. The expressed fusion protein could bind to T lymphocytes and induce strong T-cell activation. Meanwhile, a potent cytotoxicity was induced in the mixed culture of T-cell-modified tumor cells in a 96 h methyl-thiazolyl-diphenyl tetrazolium bromide assay. Our results indicate that this bifunctional protein, through activating T lymphocytes to lyse homologous human carcinomas, may be of potential value for T-cell-based immunotherapeutical treatment protocols in vivo.